Antiretroviral Drugs Market: By Drug Class (Nucleoside Reverse Transcriptase Inhibitors (NRT's), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's), Protease Inhibitors, Integrate Inhibitors, Fusion Inhibitors, Chemokine Receptor Inhibitors, Others), By Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and Geography  

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Antiretroviral Drugs Market size was valued at USD 62.9 billion in 2022 and is poised to grow at a CAGR of 3.6% from 2023-29. Cytopathic effects in cells in the brain and infected T cells may develop immune deficiencies and neurological diseases induced by HIV and related lentiviruses. Retrovirus causes immunological diseases including HIV and T-Cell leukaemia. Acquired immune deficiency syndrome (AIDS) caused by retrovirus known as human immunodeficiency virus (HIV) and T-Cell leukaemia caused by human T lymphotropic virus (HTLV). Antiretroviral drugs are the drugs that acts or inhibit certain process in viral replication and inhibits further worsening of the diseases. Globally antiviral drugs market driven by increased cases of retroviral infections such as especially HIV/AIDS. According to WHO, 36.7 million people were diagnosed with HIV/AIDS in 2015, whereas, 1.1 million people died of AIDS related illness in the same year. The higher prevalence of HIV owing to the various factors such as lack of availability of medication for the treatment of HIV infection, promising pipeline drugs, increased funding by the government are expected to bolster the antiretroviral drugs market over the forecast period. However, high costs of R&D and stringent regulatory procedures hampering the global Anti-retroviral Drugs Market. Furthermore, availability of the generic versions of blockbuster drugs affecting the market revenue of antiretroviral drugs. Antiretroviral drugs market is expected to grow at significant rates during forecasting period owing to pipeline drugs such as doravirine (Merck & Co.), fostemsavir (Bristol-Myers Squibb), rilpivirine (Tibotec) etc. Market players are adopting strategies like mergers and acquisitions to improve the market share.


Antiretroviral Drugs Market Key Developments:
  • In December 2015, ViiV Healthcare purchased Bristol-Myers Squibb's late stage HIV R&D assets. Market players are also actively collaborating with government and non-government organizations to educate the people and increase awareness related to retroviral diseases.
  • For instance, in September 2016, in an effort to eradicate and combat HIV/AIDS and hypertension in Africa, under U.S. Presidents Emergency Plan for Aids Relief (PEPFAR), United States partnered with AstraZeneca Plc in donating US$10 million to HIV/AIDS funding.
  • In November 2016, ViiV Healthcare (Pfizer and GlaxoSmithKline's joint venture) received U.S. FDA approval to market selzentry for the treatment of CCR5-tropic HIV-1 infection, in combination with other antiretroviral agents.  
     

Global Antiretroviral Drugs Market Summary

Study Period

2023-29

Base Year

2022

CAGR

3.6%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Antiretroviral Drugs Market Dynamics

However, as viral illnesses such as HIV, Herpes, Influenza, and others become more common, demand for antiviral drugs is likely to rise over the forecast period. According to UNAIDS, more than 37 million people around the world would be living with HIV by 2020. In 2020, around 1.5 million more people will have contracted HIV. Overall, the COVID-19 pandemic has greatly improved market growth in 2020, however the pandemic has had a negative influence on other antiviral drug applications. Over the predicted period, a primary element driving demand for antiviral medications is the rising incidence of viral illness over the world. According to the WHO, an estimated 325 million individuals worldwide have hepatitis, with 71 million of these having chronic hepatitis C virus infection. Furthermore, the United States Department of Health and Human Services estimates that 2.4 million people in the country have hepatitis C, with roughly 850,000 people infected with hepatitis B. The global need for antiviral medications is expected to rise as the number of patients grows.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Antiretroviral Drugs Market Segmentation

By Drug Class
  • Nucleoside Reverse Transcriptase Inhibitors (NRT?s)
  • Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s)
  • Protease Inhibitors
  • Integrate Inhibitors
  • Fusion Inhibitors
  • Chemokine Receptor Inhibitors
  • Others
By Administration
  • Oral
  • Parenteral
By Distribution channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Frequently Asked Questions

The antiretroviral drugs market size was valued at USD 62.9 billion in 2022

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

The antiretroviral drugs market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • AbbVie
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Aurobindo Pharma
  • Dr. Reddy?s Laboratories Ltd.